Lipocine is a biopharmaceutical company that researches, develops and commercializes drugs for the treatment of metaboli... Read more
Lipocine's Competitors, Revenue, Number of Employees, Funding and Acquisitions
21 Followers on Owler
President & CEO
Mahesh V. Patel
TOP COMPETITORS OR ALTERNATIVES
Repros Therapeutics is a top competitor of Lipocine. Repros Therapeutics is a Private company that was founded in 1987 in The Woodlands, Texas. Repros Therapeutics operates in the Biotechnology industry. Compared to Lipocine, Repros Therapeutics has 14 more employees.
RANK
COMPANY
CEO
CEO RATING
EMPLOYEES
FUNDING
REVENUE
Weigh-in!
Help the Owler community know moreTrending News for Lipocine and Lipocine's Competitors
July 1, 2020
BioSpace
Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders
- On-Track for September Launch of Phexxi , the First FDA-Approved, Non-Hormonal, On-Demand Prescript... See more »
July 2, 2020
The Sydney Morning Herald
Novartis pays close to $1 billion to settle suit over doctors' bribes
The pharma giant has agreed to pay the US government and various states to end a lawsuit over a sham ... See more »
July 1, 2020
MarketScreener
ObsEva : and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
(marketscreener.com) July 1, 2020 Geneva, Switzerland and Boston, MA - July 1, 2020 - ObsEva SA , and... See more »
Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$ < 1M
Lipocine's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 98.3M. Over the last three quarters, Lipocine's revenue has decreased by 97.9%. Specifically, in Q3 2019's revenue was $ < 1M; in Q1 2018, it was $ < 1M; in Q4 2012, it was $7.7M.
Acquisitions
No recent acquisitions found related to Lipocine
Lipocine Funding History
Since Lipocine was founded in 1997, it has participated in 2 rounds of funding. In total Lipocine has raised $76.0M. Lipocine's last funding round was on Aug 2013 for a total of $38.0M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
IPO
Aug 2013
$38M
Equity
Jul 2013
$38M
-
Total Funding: $76M
Since Lipocine was founded in 1997, it has participated in 2 rounds of funding. In total Lipocine has raised $76.0M. Lipocine's last funding round was on Aug 2013 for a total of $38.0M
Investments
No recent investments found related to Lipocine
Lipocine News
April 17, 2020Market Exclusive
LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
On April 17, 2020, the Company issued a press release announcing the U.S. Food and Drug Administratio... See more »
April 16, 2020DirectorsTalk Interviews
Lipocine Inc. - Consenus Indicates Potential 644.7% Upside
Lipocine Inc. found using ticker (LPCN) have now 2 analysts in total covering the stock. The consensu... See more »
April 16, 2020MarketScreener
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
(marketscreener.com) SALT LAKE CITY, April 17, 2020 /PRNewswire/ -- Lipocine Inc. , a clinical-stage ... See more »
March 26, 2020MarketScreener
Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus
(marketscreener.com) SALT LAKE CITY, March 26, 2020 /PRNewswire/ -- Lipocine Inc. , a clinical-stage ... See more »
March 26, 2020Market Exclusive
LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
The Company issued a press release announcing outcome of the Markman Hearing in the patent infringeme... See more »
March 13, 2020BioSpace
Lipocine Announces 2019 Year End Financial and Operational Results
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial r... See more »
March 13, 2020Market Exclusive
LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
On March 13, 2020, the Company issued a press release announcing financial and operational results fo... See more »
Lipocine Press Releases
April 9, 2020PR Newswire
Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on m... See more »
February 26, 2020centralcharts
Lipocine Inc. - LPCN Stock Chart Technical Analysis for 02-25-2020
News videos - Lipocine Inc. - LPCN Stock Chart Technical Analysis for 02-25-2020 - Published on 02/26... See more »
February 24, 2020centralcharts
Lipocine Announces Regulatory Path Forward for TLANDO Resubmission
Lipocine Announces Regulatory Path Forward for TLANDO Resubmission PR Newswire SALT LAKE CITY, Feb. 2... See more »
February 12, 2020centralcharts
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics PR Newswire SALT LAKE CITY,... See more »
December 13, 2019Newsfile
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - December 13, 2019) - Faruqi & Faruqi, LLP, a leading national s... See more »
November 23, 2019Newsfile
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - November 22, 2019) - Faruqi & Faruqi, LLP, a leading national s... See more »
October 14, 2019PR Newswire
Lipocine to Present at the B. Riley NASH Symposium
SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmac... See more »
Headquarters
Trending Companies
IN THE NEWS
Sophicity | Felton ICT Services | Camino Minerals | Francesca's | Guidehouse | TWE | Optus | Axis Bank | Chrysler | Associated British Foods | Nuveen | Transcelestial Technologies | Twitter | Vonage | Tellow | Ford | Xbox | FTI Consulting | Gridphilly | Converge ICT | Tru Luv | Dime Community Bancshares | BP | SBGK | Cipher Pharmaceuticals | Nissan | IATA | The Travel Network | ABB | Johnson & Johnson | Burns & McDonnell | Varta | Limelight Networks | Neighborly | NextSource Materials | Consolidated Tomoka | McCormick | YRC | Bitcoin | Lockheed Martin | Paradox | KK Group | Indigo | Spotify | e-peas | Credit Suisse | Keeneland | Mobile Klinik | Robinsons Caravans | EQUS
PEOPLE ALSO VIEWED
Trident | 007Systems | Editions Eni | Inductives | NEXTDC | IdeaSpace | AzBUL | Omniscient Analytics | IFM Investors | Anointment Natural Skin Care | Vetoquinol Usa | Doctorkepas | First N' Goal Sportscards | Jidistributors | Pro Tech Buy | Brainsonix | Esearchpro | Gascogne Groep | Ceramic Centre | Riversidebuilders | The Divins Firm | Ray White Broadbeach | Gate Theatre Company Limited(The) | nationalparksphotographer | The Splendid Table | Bardhouse | Delux Tap Service | La Guaca Restaurante | Santander Consumer Finance Benelux B.V | Csbindianola
Summary
ABOUT
Overview
Lipocine is a biopharmaceutical company that researches, develops and commercializes drugs for the treatment of metabolic and endocrine disorders. Lipocine was founded in 1997. Lipocine's headquarters is located in Salt Lake City, Utah, USA 84108. It ...
CEO
Lipocine's President & CEO, Mahesh V. Patel, currently has an approval rating of 90%. Lipocine's primary competitors are Repros Therapeutics, Antares Pharma & AMAG.Website
lipocine.comFrequently Asked Questions about Lipocine
When was Lipocine founded?
Lipocine was founded in 1997Who is Lipocine's CEO?
Lipocine's CEO is Mahesh V. PatelHow much revenue does Lipocine generate?
Lipocine generates $ < 1M in revenueHow much funding does Lipocine have?
Lipocine has historically raised $76M in funding
Where is Lipocine's headquarters?
Lipocine's headquarters is in Salt Lake City Utah, USAHow many employees does Lipocine have?
Lipocine has 10 employeesWho are Lipocine's competitors?
Lipocine's top competitors are Repros Therapeutics, Antares Pharma, AMAG
